Rare melanoma type highly responsive to immunotherapy
Moffitt Cancer Center researchers have discovered that patients with desmoplastic…
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.